This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Fireside chat scheduled for Tuesday, June 10, 2025, at 10:40am ET.NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, being held in Miami, FL on June 9-11, 2025. The fireside chat is scheduled to take place on Tuesday, June 10, 2025, at 10:40am ET. A live webcast of the fireside chat will be available on the Ev ...

Fireside chat scheduled for Wednesday, June 4, 2025, at 12:50pm ETNEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 3-5, 2025. The fireside chat is scheduled to take place on Wednesday, June 4, 2025, at 12:50 PM ET. A live webcast of the fireside chat will be avail ...

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Links to each presentation are included below. “We were pleased to present three encore presentations yesterday during the CMSC conference. We continue to be impressed by the BRIUMVI data and look forward to co ...

TG Therapeutics (NASDAQ: TGTX ) is a commercial stage biotech company, focusing on Briumvi, a treatment for multiple sclerosis. In my prior article, initiating coverage of TGTX, I gave an overview of the company and attempted to modelLike millions of other investors, I got Robinhood and started trading during the pandemic. Unlike most of those investors, I carefully studied hundreds of earnings reports for clues to future performance, and I was able to identify many future winners, such as OPRX, OTRK, FUBO, ...

Core Insights - TG Therapeutics, Inc. announced the presentation schedule for BRIUMVI (ublituximab-xiiy) data at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, focusing on its efficacy in patients with relapsing forms of multiple sclerosis (RMS) [1][2] Company Overview - TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases, with BRIUMVI approved for treating adult patients with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease [24][25] Product Information - BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, designed through glycoengineering to enhance B-cell depletion at lower doses [4] - The drug is indicated for adults with RMS, which includes various forms of the disease [6] Clinical Trials - The ULTIMATE I & II Phase 3 trials involved 1,094 patients across 10 countries, comparing BRIUMVI to teriflunomide over 96 weeks [3] - Patients in these trials had experienced at least one relapse in the previous year or had specific MRI findings [3] Presentation Details - Presentations at the CMSC meeting include topics on the safety and tolerability of BRIUMVI, with specific focus on infusion reactions and real-world observational data [2][5]

Financial Performance - TG Therapeutics reported first-quarter earnings per share of 3 cents, a shift from a loss of 7 cents a year ago, but below the consensus of 17 cents [1] - The company reported sales of $120.86 million, up from $63.47 million a year ago, beating the consensus of $118.43 million [1] Product Performance - Briumvi's U.S. net sales reached $119.7 million, demonstrating growing confidence in the treatment and increasing adoption by healthcare providers [2][3] - The company presented five-year data from the ULTIMATE I & II Phase 3 trials, showing that 92% of patients were free from disability progression after five years, with an annualized relapse rate of 0.02 during year 5 [4] - No new safety signals emerged over five years of continuous treatment, with no observed cases of progressive multifocal leukoencephalopathy (PML) [4] Future Guidance - TG Therapeutics raised Briumvi's U.S. net product revenue target to $560 million for fiscal 2025 from $525 million in prior guidance [5] - The total global revenue target was raised to $575 million from prior guidance of $540 million [5] - Briumvi's U.S. net product revenue is expected to be $135 million in the second quarter of 2025 [5] Stock Performance - TGTX stock was down 13.2% at $37.68 on Monday [6]

A near-doubling of revenue and a flip into profitability on the bottom line apparently weren't good enough for TG Therapeutics (TGTX -11.39%) shareholders on Monday.The company, best known for its multiple sclerosis (MS) drug Briumvi, posted its first-quarter results that morning, and investors expressed their displeasure by trading out of the stock aggressively. In midafternoon action its price was down by more than 14%, comparing most unfavorably to the 0.2% dip of the S&P 500 index at that point.Sales bo ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.TG Therapeutics, Inc. (NASDAQ: TGTX ), the Morrisville, North Carolina-based commercial stage Pharma company that markets and sells Briumvi (ublituximab), approved in the U ...

First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to approximately $560 million Conference call to be held today, Monday, May 5, 2025, at 8:30 AM ET NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent company developmen ...